NAV

Disufenton

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Disufenton
DrugBank Accession Number
DB17298
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 337.36
Monoisotopic: 337.028994175
Chemical Formula
C11H15NO7S2
Synonyms
  • 1,3-benzenedisulfonic acid, 4-(((1,1-dimethylethyl)oxidoimino)methyl)-
  • 2,4-disulfonyl-.alpha.-phenyl-tert-butylnitrone
  • 4-(((1,1-dimethylethyl)imino)methyl)benzene-1,3-disulfonate n-oxide
  • 4-(((1,1-dimethylethyl)imino)methyl)benzene-1,3-disulphonate n-oxide
  • 4-(((1,1-dimethylethyl)oxidoimino)methyl)-1,3-benzenedisulfonic acid
  • 4-tert-butyliminomethyl)benzene-,3-disulfonate n-oxide
  • 4-tert-butyliminomethyl)benzene-,3-disulphonate n-oxide
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Disufenton sodium7M1J3HN9VO168021-79-2XLZOVRYBVCMCGL-UHFFFAOYSA-L

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
797K01YF1M
CAS number
168021-77-0
InChI Key
OVTCHWSLKGENKP-GHXNOFRVSA-N
InChI
InChI=1S/C11H15NO7S2/c1-11(2,3)12(13)7-8-4-5-9(20(14,15)16)6-10(8)21(17,18)19/h4-7H,1-3H3,(H,14,15,16)(H,17,18,19)/b12-7-
IUPAC Name
(Z)-tert-butyl[(2,4-disulfophenyl)methylidene]oxidoazanium
SMILES
CC(C)(C)[N+](\[O-])=C\C1=C(C=C(C=C1)S(O)(=O)=O)S(O)(=O)=O

References

General References
Not Available
ChemSpider
5289390
ChEMBL
CHEMBL1206050
ZINC
ZINC000002022427
Wikipedia
Disufenton_sodium

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
3CompletedTreatmentCerebrovascular Stroke / Stroke / Stroke, Acute / Transient Ischemic Attack1
3CompletedTreatmentStroke / Transient Ischemic Attack1
2Active Not RecruitingTreatmentGlioblastoma Multiforme (GBM) of the Brain / Recurrent Malignant Gliomas1
2CompletedTreatmentCerebral Hemorrhage1
1Active Not RecruitingTreatmentRecurrent Malignant Gliomas1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.398 mg/mLALOGPS
logP-2.1ALOGPS
logP-2.1Chemaxon
logS-2.9ALOGPS
pKa (Strongest Acidic)-2.9Chemaxon
Physiological Charge-2Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area134.81 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity78.1 m3·mol-1Chemaxon
Polarizability31.55 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at December 02, 2022 20:35 / Updated at September 28, 2023 05:47